FOLH1 and neoplasm: For example, one phase II trial on 177Lu-PSMA-617 required a baseline [68Ga]Ga-PSMA-11 SUVmax at dominant sites of tumour involvement to be at least 1.5 times the SUVmean of the liver [29].